Advertisement

Topics

Latest Top Pharmaceutical Companies in Japan NewsRSS

06:40 EDT 21st October 2018 | BioPortfolio

Global ManMade Diamond Market Status and Outlook 20182025 [Report Updated: 02082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Global DNA Gyrase Subunit B EC 5.99.1.3 Market Status and Outlook 20182025 [Report Updated: 16082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Global Nickel Tube Market Status and Outlook 20182025 [Report Updated: 02082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

#Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of brigatinib Versus Crizotinib in First-Line Advanced ALK+ #NSCLC #ESMO18 https://www.businesswire.com/news/home/20181019005217/en/Takeda-Present-Results-Phase-3-ALT

#Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of brigatinib Versus Crizotinib in First-Line Advanced ALK+ #NSCLC #ESMO18 https://www.businesswire.com/news/home/20181019005217/en/Takeda-Present-Results-Phase-3-ALTA-1L-Trial …

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer

– In Patients with Brain Metastases at Baseline, ALUNBRIG Reduced the Risk of Progression in the Brain or Death by 73 Percent – – Intracranial Efficacy Data Reinforces Superiority of ALUNBRIG Versus Crizotinib in the First-Line Treatment Setting – – Data Will Be Presented in a Poster Discussion at the European Society for Medica...

Global Orally Disintegrating Tablet Market Status and Outlook 20182025 [Report Updated: 15082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Takeda moves closer to completing Shire purchase with clearance from Japanese regulators https://www.firstwordpharma.com/node/1598223 

Takeda moves closer to completing Shire purchase with clearance from Japanese regulators https://www.firstwordpharma.com/node/1598223 

Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic

Cambridge, UK, 18 October 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces it has appointed Dr Richard Williams as SVP CMC and Development, as well as a strategic CDMO partner for its lead programme, CB307, a PSMA-targeted bispecific T-cell enhancer. Richard will manage Crescendo’s internal CMC act...

Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has received unconditional clearance from the Japan Fair Trade Commission for the...

Global and Asia High Purity Aluminum Oxide Market Status and Future Forecast 20132023 [Report Updated: 21082018] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPart 3:Asia Market by company, Type, Application RegionPart 410:Key Regions of Asia Market by Type, ApplicationPart 11:Company information, Sales, Cost, Margin etc.Part 12:ConclusionMarket Segment as fo...

Global Lamp Covers Market Status and Outlook 20182025 [Report Updated: 02082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Global AntiVibration Rubber Mounts Market Status and Outlook 20182025 [Report Updated: 14082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

STAT Plus: FDA scolds Eisai after a rep makes off-label statements to doctors

The letter is seen as a significant step by the FDA, which has appeared gun-shy lately about pursuing drug makers for such behavior.

Sleep Well, Wake Up Alert: Eisai and Purdue's Lemborexant Positive in Phase III Trial for Insomnia http://dlvr.it/Qnd5z4 pic.twitter.com/4XMMHsF2bf

Sleep Well, Wake Up Alert: Eisai and Purdue's Lemborexant Positive in Phase III Trial for Insomnia http://dlvr.it/Qnd5z4  pic.twitter.com/4XMMHsF2bf

#Daiichi Submits NDA in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

#Daiichi Submits NDA in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

Daiichi Sankyo Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryDaiichi Sankyo Inc Daiichi Sankyo, a subsidiary of Daiichi Sankyo Company Ltd is a healthcare products provider that discovers and develops medicines for cardiovascular and metabolic disorders. The company's products comprise amlodipine, laninamivir, prasugrel, olmesartan esomeprazole, carvedilol and vemurafenib. It develops medicines for various therapeutic classes, such as atherosclerosis...

Takeda Pharmaceuticals USA Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryTakeda Pharmaceuticals USA Inc TPUSA, formerly Takeda Pharmaceuticals North America Inc, a subsidiary of Takeda Pharmaceutical Company Ltd, is a developer, manufacturer and distributor of pharmaceutical drugs. The company's products include pioglitazone and glimepiride, lubiprostone, pioglitazone, pioglitazone and metformin HCl, azilsartan medoxomil, alogliptin, peginesatide, lansoprazole, ...

Global Urinary Drugs Market Status and Outlook 20182025 [Report Updated: 12082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Global and Asia Zirconium Dioxide Market Status and Future Forecast 20132023 [Report Updated: 21082018] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPart 3:Asia Market by company, Type, Application RegionPart 410:Key Regions of Asia Market by Type, ApplicationPart 11:Company information, Sales, Cost, Margin etc.Part 12:ConclusionMarket Segment as fo...

Astellas Pharma Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350

Astellas Pharma Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Astellas Pharma Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by ...

Global Automated Optical Inspection Systems Market Status and Outlook 20182025 [Report Updated: 18082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Sleep Well, Wake Up Alert: Eisai and Purdue's Lemborexant Positive in Phase III Trial for Insomnia

Eisai Co. and Purdue Pharma announced topline results from their SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.

Otsuka Pharmaceutical Factory Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryOtsuka Pharmaceutical Factory Inc Otsuka, a subsidiary of Otsuka Holdings Co Ltd is a provider of parenteral and enteral nutrition products. The company's enteral nutrition products supplies nutrients such as glucose, proteins, fats, electrolytes, and vitamin. It offers over the counter products include antiseptics for treating minor skin conditions and injuries, products for treating dry s...

Taiho Ventures Expands Investment Pool to US$300 Million to Continue Quality Investments and Accelerate Open Innovation

MENLO PARK, Calif. and TOKYO, Oct. 16, 2018 /PRNewswire/ -- Taiho Ventures, LLC, a strategic corporate venture capital arm of Taiho Pharmaceutical, Co., Ltd., announced on October 16 that Taiho Ventures increased its investment pool by US$250 million from the initial US$50 million to US$300 million. The increase in the investment pool illustrates Taiho Ventures' strong commitment to its continuous...

Poxel Announces Third Quarter and Nine Months 2018 Financial Update

POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its cash posi

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Top Pharmaceutical Companies in Japan market research data and corporate reports here